Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: CellPro, Inc.

This article was originally published in The Gray Sheet

Executive Summary

Gains investigational device exemption clearance to commence clinical trials of its Ceprate B-cell depletion system in conjunction with its Ceprate SC stem cell concentration system for reducing the number of B-cells in mobilized peripheral blood used for autologous hemapoietic transplantation in patients with relapsed non-Hodgkin's lymphoma. Approximately 25 patients at the Ireland Cancer Center at University Hospitals of Cleveland, Case Western Reserve University and the University of Washington Medical Center are expected to participate in the trials, which will evaluate the safety and efficacy of B-cell purging combined with a CD34+ cell enrichment of mobilized peripheral blood. By purging lymphoma tumor cells from peripheral blood stem cell grafts, use of the system could prevent tumor cells from being returned to the patient...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT009621

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel